[Asia Economy Reporter Lee Junhyung] Cellma Therapeutics announced on the 19th that it has submitted an objection regarding its delisting.
Previously, Cellma Therapeutics received a disclaimer of opinion in the auditor's report for the last fiscal year.
The company stated, "The Korea Exchange will decide on granting an improvement period in accordance with Article 25, Paragraph 5 of the KOSPI Listing Regulations."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
